About MHAT 'Puls' AD
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Clinical Trials at MHAT 'Puls' AD
During the past decade, MHAT 'Puls' AD conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 1 clinical trials were completed, i.e. on
average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
2018-11-08
2024-09-28
Active, not recruiting
1,579
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
2018-12-27
2031-01-24
Active, not recruiting
1,240
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "MHAT 'Puls' AD" #1 sponsor was "American Regent, Inc." with 1 trials, followed by "Bayer" with 1 trials
sponsored, "Immunic AG" with 1 trials sponsored, "Kowa Research Institute, Inc." with 1 trials sponsored and "Pfizer's Upjohn has merged with Mylan to form Viatris Inc."
with 1 trials sponsored. Other sponsors include -3 different institutions and
companies that sponsored additional 7 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "MHAT 'Puls' AD"
#1 collaborator was "Brigham and Women's Hospital" with 1 trials as a collaborator, "Duke Clinical Research Institute" with 1 trials as a collaborator and "Iqvia Pty Ltd" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were
collaborators in the rest 3 trials.
Clinical Trials Conditions at MHAT 'Puls' AD
According to Clinical.Site data, the most researched conditions in "MHAT 'Puls' AD" are
"Atrial Fibrillation" (1 trials), "Chronic Obstructive Pulmonary Disease" (1 trials), "Coronary Artery Disease" (1 trials), "Dyslipidemia" (1 trials) and "Heart Failure" (1 trials). Many other conditions were trialed in "MHAT 'Puls' AD" in a lesser frequency.
Clinical Trials Intervention Types at MHAT 'Puls' AD
Most popular intervention types in "MHAT 'Puls' AD" are "Drug" (6 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (3 trials), "Apixaban" (1 trials), "Apixaban matching placebo" (1 trials), "Asundexian (BAY2433334)" (1 trials) and "Asundexian matching placebo" (1 trials). Other intervention names were less common.
Clinical Trials Genders at MHAT 'Puls' AD
The vast majority of trials in "MHAT 'Puls' AD" are
7 trials for "All" genders.
Clinical Trials Status at MHAT 'Puls' AD
Currently, there are NaN active trials in "MHAT 'Puls' AD".
undefined are not yet recruiting,
2 are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 2 completed trials in MHAT 'Puls' AD,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in MHAT 'Puls' AD, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 6 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".